1
|
Hoffe S, Kim D, Malafa M, Costello J, Aguilera T, Beg S, Parikh P, Herman J, Terry K, Holmlund J, Moser E. GRECO-2: A Randomized, Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) in Combination with GC4711 in the Treatment of Unresectable or Borderline Resectable Nonmetastatic Pancreatic Cancer (PC). Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
2
|
McDonald J, Song E, Frakes J, Extermann M, Latifi K, Kim D, Malafa M, Hodul P, Fleming J, Hoffe S. PATHOLOGIC OUTCOMES OF PATIENTS 65 AND OLDER TREATED WITH SYSTEMIC THERAPY FOLLOWED BY STEREOTACTIC BODY RADIATION THERAPY (SBRT) FOR PANCREATIC CANCER IN A NOVEL LATERAL DECUBITUS TREATMENT POSITION. J Geriatr Oncol 2019. [DOI: 10.1016/s1879-4068(19)31302-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
3
|
Jin W, Mellon E, Frakes J, Hodul P, Pimiento J, Kim R, Malafa M, Hoffe S, Fleming J. Do Health Insurance and Other Psychosocioeconomic Determinants of Health Impact Survival Through Treatment Delays with Stereotactic Body Radiation Therapy in Borderline Resectable and Locally Advanced Pancreatic Cancer Patients? Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.2013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
4
|
Song E, Frakes J, Latifi K, Malafa M, Hodul P, Pimiento J, Kim D, Kim R, Fleming J, Hoffe S. Pathologic Outcomes of Systemic Therapy Followed By Stereotactic Body Radiation Therapy for Pancreatic Cancer in a Novel Lateral Decubitus Treatment Position. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
5
|
Jin W, Mellon E, Frakes J, Murimwa G, Hodul P, Pimiento J, Soares H, Kim R, Malafa M, Hoffe S. Can Total Psoas Area Predict Toxicity After Stereotactic Body Radiation Therapy in Borderline Resectable and Locally Advanced Pancreatic Cancers? Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.977] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
6
|
Latifi K, Cruz A, Mellon E, Strom T, Freilich J, Springett G, Kim R, Malafa M, Shridhar R, Hoffe S. Metabolic Tumor Volume (MTV) Is a Predictor of Survival in Borderline Pancreatic Cancers Treated With Neoadjuvant Therapy. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
7
|
Nasir A, Lopez A, Boulware D, Malafa M, Coppola D. Correlation between COX-2 and APC expression in left versus right-sided human colon cancer. Anticancer Res 2011; 31:2191-2195. [PMID: 21737640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
BACKGROUND Because of clinicopathologic and genetic differences between left-sided colorectal cancer (LSCRC) and right-sided colon cancer (RSCC), cyclooxygenase-2(COX-2) and adenomatous polyposis coli (APC) expression may be of clinical relevance. MATERIALS AND METHODS Clinicopathologic information for 72 primary colon tumors, 44 left and 28 right, from 72 patients (34 F, 38 M) were analyzed. COX-2 and wild-type APC (W-APC) immunohistochemical expressions were determined for each case. The data were analyzed using the Chi-square test and exact binomial confidence intervals. RESULTS Overall, 31 out of 44 (70%) LSCRC were W-COX-2 positive vs. 13 out of 28 (46%) RSCC (p-value=0.042). When evaluated independently of the anatomic location, COX-2 expression showed a borderline statistical correlation with the lack of W-APC protein (p-value=0.054). When considering location of tumors, the inverse correlation between COX-2 and W-APC expression became statistically significant (p-value=0.024). CONCLUSION We report a strong inverse correlation between COX-2 and W-APC expression, with COX-2 being more frequently as expressed in LSCRC. These data may be useful to stratify colorectal cancer patients into right- and left-sided and COX-2 expressor and non-expressor subsets, when evaluating COX-2 inhibitor and other targeted therapies in colon cancer.
Collapse
Affiliation(s)
- A Nasir
- Department of Anatomic Pathology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, Florida 33612-9497, USA
| | | | | | | | | |
Collapse
|
8
|
Shibata D, Siegel E, Malafa M, Lee J, Fulp W, Jacobsen P. Adherence to National Quality Forum (NQF) colorectal cancer indicators among members of the Florida Initiative for Quality Cancer Care (FIQCC) consortium. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.6563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6563 Background: FIQCC is a consortium of 10 institutions participating in a comprehensive practice-based system of quality self-assessment across a number of cancer types. The NQF has endorsed several performance measures to assess the quality of care for colorectal cancer (CRC) patients. We have sought to identify adherence to NQF CRC indicators among members of FIQCC. Methods: Comprehensive chart reviews were conducted for all patients with CRC first seen in 2006 by a medical oncologist at one of the 10 FIQCC sites (2 academic/8 community). NQF quality measures included: 1) consideration or administration of chemotherapy to patients with stage III colon cancer (CC); 2) completeness of pathology reporting for CRC; 3) >12 regional lymph nodes (LN) examined for resected CC. Statistical comparisons were performed using chi-squared analysis. Results: The population consisted of 475 patients (250 men and 225 women) with a median age of 65 years (range 27–92). Chemotherapy was considered/administered in 96.5% (136/141) of stage III CC patients. With respect to CRC pathologic reporting, there was strong compliance (>90%) for reporting the number of LN examined and involved by tumor, proximal/distal margin status, depth of invasion, and histologic grade. However, only 225 of 295 (76.2%) reports documented lymphovascular invasion status. Radial margin status was included for 45% (27/60) of surgical rectal cancer specimens. Only 73.9% (173/234) of CC cases had >12 LN examined. Of the NQF measures, significant differences across practice sites were noted for the reporting of histologic grade (p = 0.0002), proximal/distal margin status (p = 0.049), and lymphovascular invasion (p < 0.0001). Conclusions: Although there was uniformly strong adherence to the application of adjuvant therapy for stage III CC across FIQCC sites, the adequacy of lymphadenectomy and LN examination for resected CC was lower and varied considerably across sites. There remains room for improvement of pathologic CRC reporting across the whole consortium as well as at individual sites. The FIQCC initiative allows for the identification of targets for global quality improvement as well as of specific measures for individual institutions. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- D. Shibata
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| | - E. Siegel
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| | - M. Malafa
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| | - J. Lee
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| | - W. Fulp
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| | - P. Jacobsen
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| |
Collapse
|
9
|
Jacobsen PB, Shibata D, Siegel E, Lee J, Druta M, Marshburn J, Levine R, Gondi A, Defelice J, Malafa M. Measuring quality of care in the treatment of colorectal cancer: The Moffitt Network Initiative on Practice Quality (MNIPQ). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.6001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6001 Background: As the first step in a larger effort to improve quality of care among its member institutions, the MNIPQ sought to develop and implement methods to assess quality of care in the treatment of colorectal cancer. The current report focuses on our initial experience conducting quality assessments at 4 of 20 member institutions. Methods: Medical chart reviews were conducted of all patients diagnosed with colon or rectal cancer in 2004 and seen by a medical oncologist at the Moffitt Cancer Center or at any of three affiliate institutions. Abstractors, who were trained and periodically monitored, conducted the reviews using a web-based abstraction tool. Abstraction focused on assessing adherence to quality indicators consistent with evidence-, consensus-, and regulatory-based guidelines. Variability in adherence across sites was evaluated by conducting Fisher’s exact tests. The 186 patients whose charts were reviewed were predominantly female (57%) and diagnosed with colon cancer (74%). Results: Adherence was consistently (p values>.05) high across all four study sites for: presence of a pathology report confirming malignancy (91–100%); evidence of staging based on established criteria (88–94%); documentation of discussion or referral for chemotherapy in cases of lymph node (colon and rectal cancer) or rectal wall (rectal cancer) involvement (89–100%); and presence of chemotherapy flow sheets (92–100%). Adherence was consistently (p values>.05) lower across sites for: performance of complete colon evaluation within 12 months of surgery (24–47%) and performance of CEA test before (48–74%) or in the 6 months after (56–82%) surgery or chemotherapy. Adherence varied significantly (p < .001) across sites only for documentation of consent for patients treated with chemotherapy (41–100%). Discussion: Findings identified several areas where efforts should be made to improve the quality of colorectal cancer care at one or more member institutions. In addition, the methods developed have laid the groundwork for future efforts to measure and improve quality of care for other cancers and among a larger number of member institutions. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- P. B. Jacobsen
- Moffitt Cancer Center, Tampa, FL; Space Coast Medical Associates, Titusville, FL; Center for Cancer Care and Research, Lakeland, FL; Morton Plant Hospital, Clearwater, FL
| | - D. Shibata
- Moffitt Cancer Center, Tampa, FL; Space Coast Medical Associates, Titusville, FL; Center for Cancer Care and Research, Lakeland, FL; Morton Plant Hospital, Clearwater, FL
| | - E. Siegel
- Moffitt Cancer Center, Tampa, FL; Space Coast Medical Associates, Titusville, FL; Center for Cancer Care and Research, Lakeland, FL; Morton Plant Hospital, Clearwater, FL
| | - J. Lee
- Moffitt Cancer Center, Tampa, FL; Space Coast Medical Associates, Titusville, FL; Center for Cancer Care and Research, Lakeland, FL; Morton Plant Hospital, Clearwater, FL
| | - M. Druta
- Moffitt Cancer Center, Tampa, FL; Space Coast Medical Associates, Titusville, FL; Center for Cancer Care and Research, Lakeland, FL; Morton Plant Hospital, Clearwater, FL
| | - J. Marshburn
- Moffitt Cancer Center, Tampa, FL; Space Coast Medical Associates, Titusville, FL; Center for Cancer Care and Research, Lakeland, FL; Morton Plant Hospital, Clearwater, FL
| | - R. Levine
- Moffitt Cancer Center, Tampa, FL; Space Coast Medical Associates, Titusville, FL; Center for Cancer Care and Research, Lakeland, FL; Morton Plant Hospital, Clearwater, FL
| | - A. Gondi
- Moffitt Cancer Center, Tampa, FL; Space Coast Medical Associates, Titusville, FL; Center for Cancer Care and Research, Lakeland, FL; Morton Plant Hospital, Clearwater, FL
| | - J. Defelice
- Moffitt Cancer Center, Tampa, FL; Space Coast Medical Associates, Titusville, FL; Center for Cancer Care and Research, Lakeland, FL; Morton Plant Hospital, Clearwater, FL
| | - M. Malafa
- Moffitt Cancer Center, Tampa, FL; Space Coast Medical Associates, Titusville, FL; Center for Cancer Care and Research, Lakeland, FL; Morton Plant Hospital, Clearwater, FL
| |
Collapse
|
10
|
Somani SM, Husain K, Whitworth C, Trammell GL, Malafa M, Rybak LP. Dose-dependent protection by lipoic acid against cisplatin-induced nephrotoxicity in rats: antioxidant defense system. Pharmacol Toxicol 2000; 86:234-41. [PMID: 10862506 DOI: 10.1034/j.1600-0773.2000.d01-41.x] [Citation(s) in RCA: 109] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
This study was designed to investigate the role of graded doses of lipoic acid pretreatment against cisplatin-induced nephrotoxicity. Male Wistar rats were divided into six groups and treated as follows: 1) vehicle (saline) control; 2) cisplatin (16 mg/kg, intraperitoneally); 3) lipoic acid (100 mg/kg, intraperitoneally); 4) cisplatin plus lipoic acid (25 mg/kg); 5) cisplatin plus lipoic acid (50 mg/kg) and 6) cisplatin plus lipoic acid (100 mg/kg). Rats were sacrificed three days after treatment, and plasma as well as kidneys were isolated and analyzed. Plasma creatinine increased (677% of control) following cisplatin administration alone which was decreased by lipoic acid in a dose-dependent manner. Cisplatin-treated rats showed a depletion of renal glutathione (GSH), increased oxidized GSH and decreased GSH/GSH oxidized ratio (62%, 166% and 62% of control), respectively which were restored with lipoic acid pretreatment. Renal superoxide dismutase, catalase, glutathione peroxidase (GSH peroxidase) and glutathione reductase activities decreased (62%, 75%, 62% and 80% of control), respectively, and malondialdehyde content increased (204% of control) following cisplatin administration, which were restored with increasing doses of lipoic acid. The renal platinum concentration increased following cisplatin administration, which was possibly decreased by chelation with lipoic acid. The data suggest that the graded doses of lipoic acid effectively prevented a decrease in renal antioxidant defense system and prevented an increase in lipid peroxidation, platinum content and plasma creatinine concentrations in a dose-dependent manner.
Collapse
Affiliation(s)
- S M Somani
- Department of Pharmacology, Southern Illinois University School of Medicine, Springfield 62794-9629, USA.
| | | | | | | | | | | |
Collapse
|
11
|
Touliatos JS, Neitzel L, Whitworth C, Rybak LP, Malafa M. Effect of cisplatin on the expression of glutathione-S-transferase in the cochlea of the rat. Eur Arch Otorhinolaryngol 2000; 257:6-9. [PMID: 10664037 DOI: 10.1007/pl00007509] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Glutathione-S-transferase (GST) has been found to conjugate glutathione (GSH) to diverse electrophiles and play a major role in the detoxification of alkylating and platinating agents. However, there is little information regarding the pattern of GST expression in the cochlea. Although cisplatin is ototoxic, its effect on GST in the cochlea is unknown. In the present study we investigated the pattern of GST expression in control and cisplatin-treated cochleas by using the laboratory rat as animal model. Sixteen mature rats were randomly assigned to control or cisplatin groups. After treatment, cochleas were procured and tissues stained by immunohistochemical methods to detect the presence of GST. Optical density measurements were determined to gauge intensity of GST immunostaining. Strong positive GST immunostaining was demonstrated in all cochleas, with the most intense staining found in the spiral ligament and the least in Reissner's membrane. Mean optic density scores were lower for cisplatin-treated cochleas than for control cochleas in all areas analyzed. These findings showed that GST is expressed throughout the rat cochlea, with cisplatin treatment causing its decreased expression.
Collapse
Affiliation(s)
- J S Touliatos
- Department of Surgery, Southern Illinois University, School of Medicine, P.O. Box 19638, Springfield, IL 62794-9638, USA
| | | | | | | | | |
Collapse
|
12
|
Abstract
BACKGROUND Manganese superoxide dismutase (MnSOD) catalyzes the scavenging of superoxide radicals in order to protect cells from the damage caused by reactive oxygen species. Previous studies implicate MnSOD in cancer progression, but its role in gastric cancer metastasis is poorly understood. MATERIALS AND METHODS To determine whether MnSOD expression correlates with gastric cancer metastasis, we compared immunostaining for MnSOD in the primary tumors of gastric cancer patients with (n = 15) and without (n = 9) nodal metastases. These patients were matched for risk factors associated with gastric cancer metastasis, such as tumor site, depth, and grade. MnSOD expression was scored positive (increased) if MnSOD staining of tumor cells was more intense than MnSOD staining in corresponding normal gastric epithelial cells. Statistical analyses were via chi(2) test and Fisher's exact test. RESULTS MnSOD expression was increased in 14 of the 15 (93%) metastatic tumors, compared to only 4 of the 9 (44%) nonmetastatic tumors (P = 0.015). There was no significant difference in staining when the two groups were compared based on tumor grade (P = 0.70) or depth of tumor cell invasion (T stage) (P = 0.22). CONCLUSIONS MnSOD expression is upregulated in the primary tumors of gastric cancer patients with lymph node metastases. This finding supports an involvement of MnSOD and possibly the reactive oxygen status of the gastric tumor microenvironment in gastric cancer metastasis.
Collapse
Affiliation(s)
- M Malafa
- Department of Surgery, Southern Illinois University School of Medicine, Springfield, Illinois 62794, USA
| | | | | | | | | |
Collapse
|
13
|
Darabi A, Gross S, Watabe M, Malafa M, Watabe K. Differential gene expression in experimental hepatocellular carcinoma induced by woodchuck hepatitis B virus. Cancer Lett 1995; 95:153-9. [PMID: 7656224 DOI: 10.1016/0304-3835(95)03881-v] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Hepatitis B virus infection is closely linked to hepatocellular carcinoma (HCC), the pathological mechanism of hepatocarcinogenesis by this virus is not well understood. In order to gain further insight into the molecular mechanism of HCC, we constructed and screened a subtracted c-DNA library which was specific to HCC cells of a woodchuck infected with woodchuck hepatitis B virus. Among eight clones that were isolated based on their differential expressions, we determined nucleotide sequences of two genes whose expressions were most significantly stimulated in HCC. Our results indicate that these two genes appear to be woodchuck counterpart genes of hemopexin (HPX) and alpha-1 acid glycoprotein (AGP), suggesting that the expression of HPX and AGP genes are strongly augmented in tumor cells partly due to transcriptional regulation.
Collapse
Affiliation(s)
- A Darabi
- Department of Medical Microbiology and Immunology, School of Medicine, Southern Illinois University, Springfield 62702, USA
| | | | | | | | | |
Collapse
|
14
|
Chaudhuri B, Crist KA, Mucci S, Malafa M, Chaudhuri PK. Distribution of estrogen receptor in ductal carcinoma in situ of the breast. Surgery 1993; 113:134-7. [PMID: 8381562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
BACKGROUND Long-term antiestrogen therapy has been suggested as a possible treatment alternative for ductal carcinoma in situ (DCIS) of the breast. However, very little information is available on the distribution of estrogen receptor (ER) and treatment success with antiestrogen for such lesions. METHODS Thirty-two formalin-fixed tissue specimens of DCIS from 32 female patients aged 38 to 71 years were evaluated for the presence of ER by an immunoperoxidase technique. Antigenic sites for ER were exposed by treating the tissue sections with deoxyribonuclease followed by peroxidase-antiperoxidase staining with monoclonal antibody against ER. Parallel negative controls were run with negative control monoclonal antibody and normal rat serum. The quality control for positive staining was performed with tissue sections from specimens with known ER detected by the radioreceptor method. RESULTS Eighteen (60%) of the 32 lesions were positive for ER. In 7 of the 18 lesions less than 25% of cells stained positive for ER and in 4 of the 18 more than 50% of cells stained positive for ER. CONCLUSIONS The incidence of ER in DCIS is similar to the incidence of ER in invasive carcinoma, leading to the speculation that ER-positive invasive carcinoma originates from an ER-positive precursor lesion. Because only 60% of the cases have detectable ER and approximately 70% of positively stained ERs are expected to be functional (as in invasive carcinoma), it appears that approximately 42% of the patient population with DCIS will benefit from antiestrogen therapy.
Collapse
Affiliation(s)
- B Chaudhuri
- Department of Pathology, Medical College of Ohio, Toledo 43699-0008
| | | | | | | | | |
Collapse
|
15
|
Malafa M, Mancini MC, Myles JL, Gohara A, Dickinson JM, Walsh TE. Successful treatment of acute humoral rejection in a heart transplant patient. J Heart Lung Transplant 1992; 11:486-91. [PMID: 1610857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Eight months after undergoing orthotopic heart transplantation, a patient had hypotension and biventricular heart failure. Endomyocardial biopsy specimens showed a modest cellular infiltrate, predominantly of plasma cells, and progressive myocyte injury, suggesting a humoral rejection process. The patient was treated with Minnesota antilymphoblast globulin and aggressively with plasmapheresis, resulting in evidence of myocyte repair, improved hemodynamics, and long-term survival.
Collapse
Affiliation(s)
- M Malafa
- Department of Surgery, Medical College of Ohio, Toledo 43699-0008
| | | | | | | | | | | |
Collapse
|
16
|
Malafa M, Chaudhuri B, Thomford NR, Chaudhuri PK. Estrogen receptors in ductal carcinoma in situ of breast. Am Surg 1990; 56:436-9. [PMID: 2164337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
A number of investigators have suggested treatment of precursor lesions for invasive breast cancer such as ductal carcinoma in situ with antiestrogen. However, very little information is available on the incidence of estrogen receptor in such lesions and the probability of treatment success. Fourteen formalin-fixed tissue specimens of intraductal carcinoma in situ from 14 female patients aged 40 to 66 years were evaluated for the presence of estrogen receptor by immunoperoxidase technique using estrogen receptor antibody. Eight of the 14 lesions (57%) were positive for estrogen receptor. The incidence of estrogen receptor in intraductal carcinoma in situ is very similar to that of invasive carcinoma of breast, leading to the speculation that ER-positive invasive carcinoma originates from ER-positive precursor lesions. Since only 70 per cent of positive receptor lesions are expected to respond to antiestrogens, it appears that only 40 per cent of patients with ductal carcinoma in situ of breast will benefit from endocrine therapy.
Collapse
Affiliation(s)
- M Malafa
- Department of Surgery, Medical College of Ohio, Toledo 43614
| | | | | | | |
Collapse
|
17
|
Abstract
A patient is presented with multiple vascular anomalies in the branches of the celiac axis as well as in the portal vein and its branches. Apparently, unique in the literature is the presence of a large arteriovenous fistula between the hepatic artery and one of the hepatic veins. The anomalies are presumed to be congenital in origin.
Collapse
Affiliation(s)
- J M Howard
- Department of Surgery, Medical College of Ohio, Toledo 43699
| | | | | | | |
Collapse
|